Harbor Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Harbor Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,851	Closed	-$253K	–	1423
2024 Q4	$253K	Buy	3,851 +93	+2%	+$6.23K	0.01%	632
2024 Q3	$264K	Buy	3,758 +15	+0.4%	+$1.25K	0.01%	643
2024 Q2	$308K	Buy	3,743 +11	+0.3%	+$916	0.02%	605
2024 Q1	$326K	Buy	3,732 +373	+11%	+$33.4K	0.04%	502
2023 Q4	$324K	Buy	3,359 +1	+0%	+$88	0.06%	306
2023 Q3	$297K	Hold	3,358	–	–	0.06%	308
2023 Q2	$291K	Hold	3,358	–	–	0.06%	323
2023 Q1	$327K	Buy	+3,358	New	+$348K	0.09%	177

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbor Capital Advisors's BMRN Position: Q1 2025 in Review

Harbor Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 3,851 shares — an estimated $253K sold.

Harbor Capital Advisors first reported a position in BMRN in Q1 2023 and held it in 8 quarters. The position peaked at $327K in Q1 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Harbor Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Harbor Capital Advisors sold 3,851 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $253K.
Harbor Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 8 quarters.
Harbor Capital Advisors's BioMarin Pharmaceuticals position peaked at $327K in Q1 2023.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Harbor Capital Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.